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Abstract
In the field of herpesvirus research, the exact molecular mechanism by which such viruses reactivate from latency remains
elusive. Kaposi’s sarcoma-associated herpesvirus (KSHV) primarily exists in a latent state, while only 1–3% of cells support
lytic infection at any specific time. KSHV reactivation from latency is an exceedingly intricate process mediated by the
integration of viral and cellular factors. Previously, our lab has described early growth response-1 (Egr-1) as an essential
component for the KSHV reactivation process via its ability to mediate transcription of KSHV ORF50, the gene encoding for
replication and transcription activator (RTA), a viral component known to control the switch from latent to lytic infection. In
here, electrophoretic mobility shift assays (EMSA) and chromatin immunoprecipitation (ChIP) experiments revealed that Egr-
1 binds KSHV ORF50 promoter (ORF50P) in at least two different GC-rich binding domains. Expression profiles of cellular egr-
1 and KSHV-encoded ORF50 follow a similar pattern during de novo KSHV infection. Over-expressing Egr-1, a signaling
component downstream of Raf.MEK.ERK1/2, in KSHV-infected cells activates KSHV lytic replication. Through performing
more physiologically relevant experiments, we analyzed the effect of a dietary supplement containing resveratrol on KSHV-
infected cells. Our results, for the first time, demonstrate resveratrol to act in lowering ERK1/2 activity and expression of Egr-
1 in KSHV-infected cells, resulting in the suppression of virus reactivation from latency. Taken together, these findings will
undoubtedly contribute to future studies on not only combating KSHV related disease conditions, but also on other
herpesviruses-induced pathogenesis.
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Introduction
Significant strides have been made since the discovery of
Kaposi’s sarcoma-associated herpesvirus (KSHV) by Chang et al
[1] nearly 20 years ago that have helped to increase our
understanding of this infectious agent. KSHV is a c2-herpesvirus
that has been directly linked to the development of Kaposi’s
sarcoma (KS), primary effusion (PEL), and multicentric Castleman
disease (MCD). This virus is closely related to Epstein-Barr virus
(EBV), murine gammaherpesvirus-68, and herpesvirus saimiri [2].
The prevalence of KSHV infection varies depending on the
geographical location with highest levels observed in Africa, where
it has been reported to be greater than 40% [3]. As KSHV
displays several characteristics shared among other herpesviruses,
its ability to switch between latent and lytic stages of infection is of
particular concern. The virus remains predominantly in a latent
state, while 1–3% of cells may support a lytic infection at any given
time [4]. Regulation of the switch between the two stages of
infection is mediated by viral and cellular factors. Specifically, the
KSHV protein, replication and transcription activator (RTA), is
known to be a crucial viral component controlling the transition
from latency to a lytic infection [5]. Recently, cellular early growth
response-1 (Egr-1) protein was also shown to be an important
factor involved in KSHV reactivation through its ability to
mediate transcription of KSHV ORF50, the gene encoding RTA
[6].
Egr-1 is a transcription factor that is also known as zif268,
Krox-24, NGFI-A, and TIS8 [7]. It is induced by several external
stimuli including growth factors, different forms of stress, and
hormones. As a result of stimulation from various factors, egr-1
gene products advance to play a role in several cellular functions
such as, but not limited to, growth, proliferation, and differenti-
ation [8]. Egr-1 is part of a zinc-finger gene family that includes
Egr-2, Egr-3, Egr-4, and the Wilms tumor suppressor (WT1) [9].
TPA is used to activate a lytic infection in KSHV-infected cells
[10]. Egr-1 mediates the effect of TPA activation and is a
downstream target of MAPK signaling [9,11]. Furthermore,
MAPK signaling is crucial for triggering KSHV reactivation from
latency [12,13]. However, despite the ability of Egr-1 and KSHV
ORF50 to interact with each other, there is little information
available describing this association.
In a recent study, the ability of Egr-1 to bind KSHV ORF50
promoter (ORF50P) was described [6]. In this report, electropho-
retic mobility shift assays (EMSA) and chromatin immunoprecip-
itation (ChIP) experiments were employed to determine the
locations on ORF50P that have an affinity for Egr-1 binding. Our
results demonstrated at least two targets that are likely crucial for
mediating Egr-1 binding to ORF50P. These findings were
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tested the ability of resveratrol, a naturally occurring product
found in a variety of fruits and nuts [14], in regulating MAPK
signaling.Egr-1 expression.promoting virus latency. As such, the
ramifications on the ability of Egr-1-induced transcription of
ORF50 in viral pathogenesis are discussed.
Results
Egr-1 binds at least two different sites within the ORF50P
Egr-1 is said to bind a GC-rich DNA template (such as
GCGC(G/T)GGGCG, GCGGGGGCG, and CGCCCATGC)
on the promoter and initiate gene transcription [15,16]. Eight
possible GC-rich Egr-1 binding sequences have been identified by
us in the promoter region of KSHV ORF50. In order to determine
the sites where Egr-1 bound ORF50P, EMSA experiments were
performed using 8 different DIG-labeled probes, referring to
identified locations on ORF50P, (Table 1) and Egr-1 in vitro
transcribed and translated (IVT) proteins. IVT of egr-1/
pcDNA3.1(+) construct yielded a protein of roughly 78 kda (data
not shown) [6]. Of all the probes tested, IVT-synthesized Egr-1
proteins were able to bind and form separate protein:DNA
complexes with the ORF50P3 and ORF50P8 probes, respectively;
displaying distinct band shifts when compared to controls using the
probes alone (Fig. 1A; lanes 6 and 16). It is important to note that
the sequence for ORF50P3 is the same for the probe used in earlier
study [6]. Band shifts were not observed when ORF50P probes
were incubated with IVT-synthesized KSHV glycoprotein L (gL)
(data not shown). Additionally, experiments using the ORF50PNP
probe (does not contain the GC-rich binding domain) did not form
a complex with Egr-1 protein, thus confirming the specificity of
Egr-1 binding (Fig. 1A, lane 18). Finally, competition experiments
using unlabeled ORF50P probes reduced band shifts by preventing
Egr-1 binding to DIG-labeled probes (data not shown).
A second set of EMSA studies were conducted using ORF50P
probes carrying mutations (ORF50P3m and ORF50P8m; Table 1)
in the putative Egr-1 binding region to further confirm the binding
ability of Egr-1 proteins. Briefly, ORF50P3 and ORF50P8 were
mutated to carry the 5 bp ATATA sequence in the GC-rich
binding domain and then incubated in binding buffer alone or
with IVT-synthesized Egr-1. Samples consisting of wildtype (wt) or
mutated probes alone did not display a shift in the respective
ORF50P3 and ORF50P8 probes (Fig. 1B; lanes 1, 3, 5. and 7).
Following incubation of wt probes with Egr-1, complexes were
formed producing separate band shifts (Fig. 1B, lane 2 and 6).
Interestingly, Egr-1 did not bind ORF50P3m or ORF50P8m
probes that displayed mutations in the Egr-1 binding domain, thus
confirming the necessity for the consensus GC-rich binding
domain mediating Egr-1/ORF50P interactions (Fig. 1B, lanes 4
and 8).
Finally, gel shift assays were performed using the nuclear
extract from KSHV-infected cells to verify the ability of Egr-1 to
bind ORF50P3 and ORF50P8. As expected, there was no
hindrance in the migration of ORF50P probes without the
addition of cell lysate (Fig. 1C; lanes 1 and 5). However, the
presence of the lysate in the samples resulted in the formation of
protein:DNA complexes indicated by a band shift (Fig. 1C, lanes
2 and 6). Egr-1 binding to ORF50P was confirmed by incubating
lysates with specific Abs and performing a supershift. Samples
that were incubated with nonspecific IgG Abs displayed band
shifts that were similar to samples containing only Egr-1 and the
respective probes (Fig. 1C, lanes 3 and 7). Alternatively, a
supershift occurred exhibiting a discrete band when nuclear
lysates were pre-treated with Egr-1 specific Abs (Fig. 1C, lanes 4
and 8). Taken together, these experiments provide support for the
ability of Egr-1 to specifically bind to two separate locations on
KSHV ORF50P.
Figure 1. Egr-1 binds two different targets on the KSHV
ORF50P. (A) IVT-synthesized Egr-1 binds to ORF50P probes. EMSA
studies were performed using IVT-synthesized Egr-1 products and DIG-
labeled ORF50P probes (see Table 1). (B) Mutations in the putative Egr-1
binding domain inhibit Egr-1 binding. EMSA experiments were
performed using wt ORF50P3 and ORF50P8 probes as well as
corresponding probes displaying mutations in the suspected Egr-1
binding domain (ORF50P3m and ORF50P8m). (C) Nuclear lysates from
KSHV-infected cells formed a complex with ORF50P probes. BCBL-1 cells
were synchronized in S phase of cell cycle according to earlier protocols
[28], treated with 20 ng/ml TPA for 8 h, and lysed. Nuclear extracts
containing Egr-1 proteins were used to perform EMSA studies using
ORF50P3 and ORF50P8 probes. Specific Egr-1 binding was confirmed by
performing supershifts using specific antibodies to Egr-1 (lanes 4 and 8)
or nonspecific IgGs (lanes 3 and 7). The arrowhead indicates protein/
DNA complex formation. Specific antibody/protein/DNA supershifts are
denoted by the asterisk.
doi:10.1371/journal.pone.0033364.g001
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A semi-quantitative chromatin immunoprecipitation (ChIP)
assay was performed to analyze Egr-1 binding to ORF50Pi na
chromatin context (in vivo) using specific antibodies. TPA-induced
KSHV-infected cells were used to assess the binding ability of Egr-
1t oORF50P via ChIP assays. The presence of specific ORF50Pi n
the IP samples was analyzed by semiquantitative PCR using
specific primers covering the regions of ORF50P3 or ORF50P8. As
expected, when Egr-1 was expressed in BCBL-1 cells it was
recruited to the promoter of KSHV ORF50 and specifically
targeted both ORF50P3 and ORF50P8 (Fig. 2A, cycle 30).
Recruitment of Egr-1 to the nonspecific ORF50NP region was
not detectable in our experiments (data not shown). For negative
controls, samples were IP with nonspecific (NS) IgG Abs and
recruitment of Egr-1 to ORF50P was not observed (Fig. 2A, cycle 30
on control gels). However, positive controls using specific Abs to
histone proteins recovered ORF50P targets (Fig. 2A). These results
help us confirm that Egr-1 binds to two separate domains on
ORF50P, in vivo.
To establish a critical role for these interactions between Egr-1
and ORF50P, luciferase reporter constructs were used to
investigate the necessity of ORF50P3 and ORF50P8 during Egr-
1-mediated activation of the ORF50P. Empty vector (pGL3) or
vectors encoding a deletion series of ORF50P (Fig. 2B) along with
the downsteam luciferase gene were transiently transfected into
target cells in conjunction with empty vector or egr-1/
pcDNA3.1(+). Cells transfected with pcDNA3.1(+) did not induce
significant luciferase activity (Fig. 2C). However, following
incubation of cells transfected with egr-1/pcDNA3.1(+), we noticed
the luciferase activity to be significantly greater in cells that were
also transfected with constructs encoding the full length (FL)
ORF50P compared to cells transfected with pGL3 (Fig. 2C),
Furthermore, we observed a decrease in relative luciferase activity
following deletion of the fragment containing the ORF50P3
domain (D-2922 to -2044; D-2922 to -1322; D-2922 to -894; and
D-2922 to -169) when compared to the construct encoding full
length ORF50P (Fig. 2C). Although the absence of ORF50P3
contributed to a decrease in luciferase activity, this activity was
never completely abolished (Fig. 2C) suggesting the need for an
intact ORF50P3 and ORF50P8 for an optimal Egr-1-induced
transcription of ORF50. Taken together, these results suggest a role
for Egr-1 to specifically bind and activate ORF50P to trigger a lytic
infection in KSHV-infected cells.
Cellular Egr-1 and virus-encoded KSHV RTA follow a
similar expression pattern during de novo KSHV infection
Several different viruses are known to activate Egr-1 expression
upon infection [17,18,19,20]. Since BCBL-1 cells already carry
KSHV DNA, KSHV-infected HEK293 cells were used to
evaluate the expression pattern of Egr-1 and KSHV RTA during
early stages of de novo infection. Expression of Egr-1 and RTA
proteins were significantly elevated by 1 hour post infection (hPI)
and continued to maintain increased expression until roughly 6–
8 hPI (Fig. 3A, lanes 2–4). In contrast, a considerable decrease in
the expression of these proteins was observed from 12–48 hPI
(Fig. 3A, lanes 5–7). A significant difference in expression of total b-
actin was not observed (Fig. 3A) during the course of KSHV
infection demonstrating the specificity of the results on Egr-1 and
RTA expression.
To further support our findings, mRNA extracted from KSHV-
infected HEK293 cells were subjected to quantitative real-time
PCR (qRT-PCR) analysis in order to evaluate egr-1 and ORF50
transcriptional activity. Uninfected cells (0 hPI) did not show
detectable ORF50 expression (Fig. 3B). On the other hand, a low
baseline level of egr-1 expression was observed in the uninfected
samples (Fig. 3B). With the onset of a primary infection, expression
levels of both egr-1 and ORF50 increased up to 6hPI (Fig. 3B).
These elevated levels of egr-1 and ORF50 decreased substantially
by 12–24 hPI (Fig. 3B). No significant changes in the expression of
the internal control gene encoding M6PR was observed indicating
specificity of the results (data not shown). Taken together, the
expression profiles of Egr-1 and RTA seem to follow an identical
pattern during primary infection of cells.
Elevated Egr-1 expression activates lytic genes in KSHV-
infected cells
BCBL-1 cells have turned out to be a blessing in disguise for
this study as they harbor KSHV DNA in a predominantly latent
state [21]. BCBL-1 cells were transiently transfected using egr-1/
pCDNA3.1(+) for 24, 48, and 72 h (Fig. 4A; lanes 4, 5, 6). The
highest expression of Egr-1 was observed by 48 h post
transfection; followed by a reduction in the next 24 h. Target
cells that were untransfected (Fig. 4A; lane 1), mock transfected
(Fig. 4A; lane 2), and transfected with empty vectors (Fig. 4A; lane
3) did not display an observable difference in Egr-1 expression.
Next, qRT-PCR studies were performed to identify changes in
egr-1 and virus-encoded ORF50 gene expression. We did not
observe any noticeable alterations in egr-1 and ORF50 transcrip-
tion in target cells that were untransfected (UT), mock
transfected, or transfected with empty vectors (Fig. 4B). As
expected, levels of egr-1 were significantly increased in cells
transfected with egr-1/pCDNA3.1(+) over controls (Fig. 4B).
Furthermore, elevated egr-1 expression coincided with an increase
in KSHV ORF50 transcription (Fig. 4B). Peak expression for
both genes was observed by 48 h post transfection (Fig. 4B).
Incidentally, we also observed an elevated expression of ORF8
(Fig. 4B), encoding the late structural virus protein termed as gB,
in response to an enhanced egr-1 and ORF50 expression. All these
changes implicate Egr-1 expression to significantly induce virus
reactivation.
Immunofluorescence assay (IFA) was conducted to determine a
possible role for elevated Egr-1 on the expression of KSHV-
encoded lytic proteins in the above transfected cells (Fig. 4A, B).
KSHV-encoded ORF59, a processivity factor for KSHV DNA
Table 1. KSHV ORF50P Region 3087 bp (68608–71694 as per
NC_009333.1).
Probe Sequence Location on ORF50
ORF50P1 atggccttgcgcccccacaggagaa
22766 -
22742
ORF50P2 tgagccggccctccccttctccacc
22665 -
22641
ORF50P3 tttgacctgcgtgcgctctccggct
22173 -
22149
ORF50P3m tttgacctatatacgctctccggct
22173 -
22149
ORF50P4 tatgccggggtgcgcgggggtcccg
21320 -
21296
ORF50P5 tttcctggtggggcgcggcagctga
2994 -
2970
ORF50P6 ctctgcccatgggcgggtgggtgac
2952 -
2928
ORF50P7 tcattaagccccgcccagaaaccag
2119 -
295
ORF50P8 aaccagtagctgggtggcaatgaca
2100 -
276
ORF50P8m aaccagtagctatatagcaatgaca
2100 -
276
ORF50NP caaatagtcgttggctaggttaaag
22911 -
22887
doi:10.1371/journal.pone.0033364.t001
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early stages of virus reactivation [22]. Target cells transfected with
empty vectors showed low levels of ORF59 expression (Fig. 4C).
However, transfection cells with egr-1/pcDNA3.1(+) augmented
the level of ORF59 protein expression in KSHV-infected cells
(Fig. 4C); clearly implicating a critical role for Egr-1 in inducing
KSHV reactivation.
Finally, we analyzed MAPK signaling in the above cells relative
to Egr-1 expression levels. Our results suggest that cells transfected
with egr-1/pCDNA3.1(+) displayed elevated levels of Egr-1
(Fig. 4D, lane 7). Transfection of cells with pCDNA3.1(+)
(Fig. 4D, lane 5) or mock transfection (Fig. 4D, lane 3) of cells did
not significantly alter the expression levels of Egr-1 and
phosphorylation state of ERK1/2 compared to untransfected cells
(Fig. 4D, lane 1). Interestingly, treatment of cells with a known
inhibitor of MEK1/2 (10 mM of U0126) significantly lowered both
the expression levels of Egr-1 and ERK1/2 activity (Fig. 4D, lane
8). We observed U0126 to dose dependently inhibit ERK1/2
activity and Egr-1 levels in the above cells confirming the
specificity of U0126 in targeting MAPK.Egr-1 signaling. The
inhibition of ERK1/2 activity and Egr-1 levels was greatest
following treatment of infected cells with 10 mM of U0126 (Fig. 4E,
lane 4). These results suggest Egr-1 to be downstream of the
MAPK signaling cascade.
Figure 2. Egr-1 targets KSHV ORF50 in vivo. (A) BCBL-1 cells were synchronized in S phase [28] and treated with 20 ng/ml of TPA for 8 h. ChIP
assays were performed using 2 mg of specific antibodies to Egr-1 or nonspecific IgGs. Primers specifically targeting ORF50P3 or ORF50P8 (see Table 1)
were used to perform semi-quantitative PCR experiments on 1% of total DNA (input) and IP samples. Respective cDNA at 10, 15, 20, 25, and 30 cycles
were removed and resolved on a 2% agarose gel. IP of BCBL-1 DNA using specific antibodies to histone H3 was used as positive controls. (B)A
schematic representation of ORF50P used to make the deletions of the luciferase reporter constructs. The nucleotide locations correspond to the old
KSHV genome sequence NC_003409 which has since been updated to NC_009333.1. Asterisks refer to the ORF50P3 and ORF50P8 locations,
respectively. (C) Overexpression of Egr-1 activates ORF50P via interacting with ORF50P3 and ORF50P8 domains. HEK293 cells were co-transfected with
a combination of three vectors, one from the following groups: (i) pcDNA3.1(+)o regr-1/pcDNA3.1(+), (ii) the control vector, pRL-TK, and (iii) empty
pGL3 vectors or pGL3 vectors encoding FL ORF50P or one of several deletions (D-2922 to -2044; D-2922 to -1322; D-2922 to -894; and D-2922 to -169).
After 48 h post-transfection, the cells were lysed, and relative luciferase activity was monitored. Firefly luciferase was normalized to the
corresponding Renilla luciferase activity. The luciferase activation of pGL3 by egr-1/pcDNA3.1(+) was represented as 1-fold. Each point denotes the
average 6 SD of three experiments. Columns with different alphabets are statistically significant (P,0.05) by least significant difference (LSD).
doi:10.1371/journal.pone.0033364.g002
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late stages of infection
Due to the vital role of MAPK signaling on Egr-1 expression
and KSHV reactivation, the effect of resveratrol on KSHV
replication was analyzed. We chose to use resveratrol because: (i) it
is a naturally occurring product; and (ii) it is a known regulator of
MAPK signaling and Egr-1 expression [14]. Furthermore,
resveratrol inhibits ERK1/2 activity in virus-infected cells [23].
It is important to understand that even though KSHV-encoded
ORF50 is a gene crucial for reactivation, it is also expressed during
early stages of KSHV infection and may play a role in the
establishment of virus latency [6,24]. Therefore, it was necessary
to determine the expression pattern of cellular egr-1 and virus-
encoded ORF50 during both early stages of infection as well as
during virus reactivation (late stages). In this study, effect of
resveratrol on early stages of infection was analyzed in HEK293
cells while its effect on late stages (reactivation using TPA) was
analyzed predominantly in BCBl-1 cells, for convenience. In this
study, resveratrol was able to inhibit egr-1 expression in a dose
dependent manner during early stages of de novo KSHV infection
of HEK293 cells (Fig. 5A). The doses tested in this study were
confirmed by trypan blue test to be non-toxic to cells (data not
shown). The resveratrol doses used by us are also those that have
been published previously [25,26,27]. Resveratrol (100 mM) was
able to suppress the expression of phospho-ERK1/2 and Egr-1
proteins during de novo infection of cells (Fig. 5B, lanes 3, 6, and 9).
Additionally, resveratrol was able to inhibit the expression Egr-1
and phophorylated ERK1/2 in mock-infected cells (Figure S1,
lanes 2, 4, and 6). On the other hand, it was not able to significantly
alter the expression of endogenous ERK1/2 and actin controls
(Fig. 5B, lanes 3, 6, and 9; Figure S1, lanes 2, 4, and 6). DMSO, the
vehicle for resveratrol, did not significantly alter the phosphory-
lation of ERK1/2 and the expression of Egr-1 (data not shown).
In order to present more physiologically relevant studies, an
over-the-counter resveratrol dietary supplement (RDS) was used to
treat KSHV-infected BCBL-1 cells under TPA-induced condi-
tions. RDS containing 100 mM resveratrol did not significantly
induce cell death as monitored by the lactate dehydrogenase assay
(data not shown). These results were confirmed by the conven-
tional trypan blue test. More than 95% of the target cells were
found to be viable when the target cells were treated with RDS
(data not shown). As shown in earlier reports [12], TPA treatment
augments phospho-ERK1/2 expression (Fig. 6A, lane 2). The
effect of TPA also resulted in an increase in Egr-1 and KSHV
RTA expression when compared to uninduced cells (Fig. 6A, lane
2). Unfiltered RDS successfully inhibited phospho-ERK1/2, Egr-
1, and RTA expression in TPA-induced KSHV-infected cells
(Fig. 6A, lane 3). A slightly lesser inhibitory effect was observed in
cells that were treated with RDS that had particulates removed
using a 0.2 mm filter (Fig. 6A, lane 4). We did not discover either
form of RDS to have noticeable effect on endogenous ERK1/2
and actin controls (Fig. 6A, lanes 3 and 4). The data from Western
blotting (Fig. 6A) was further confirmed in HEK293 cells by IFA
(Fig. 6B). To authenticate the results from monitoring the effect of
RDS on protein levels of Egr-1 and RTA, we analyzed the effect of
RDS on (i) uninduced cells transfected with vectors encoding egr-1,
and (ii) TPA-induced KSHV reactivation in BCBL-1 cells by
performing qRT-PCR. Our results clearly demonstrate the ability
of RDS to lower the expression of both egr-1 and ORF50 under
both circumstances (Fig. 6C, D). Finally, ChIP assay was
performed to discern the specificity of RDS on virus reactivation
using primers specific to ORF50P8 region. Under TPA-induced
conditions, Egr-1 specifically targeted ORF50P8 (Fig. 6E. cycles 25
and 30). However, under RDS treated conditions the binding of
Egr-1 to ORF50P8 was significantly decreased (Fig. 6E, cycles 25
and 30). For negative controls, samples were IP with (NS) IgGs and
recruitment of Egr-1 to ORF50P was not observed (Fig. 6E).
However, positive controls using specific Abs to histone proteins
recovered ORF50P targets (Fig. 6E). These results suggest
resveratrol in its chemical form and RDS may lower Egr-1
expression to inhibit KSHV reactivation from latency.
Discussion
Egr-1 regulates expression of several viral genes and plays a
crucial role in the replication of different viruses Our results from
employing the EMSA and ChIP assay (Fig. 2A) demonstrate that
Egr-1 may bind ORF50P via at least two different GC-rich binding
domains: at positions between
2100 –
276 bp (ORF50P8) and
22173 –
22149 bp (ORF50P3). The results from employing the
ChIP assay (Fig. 2A) demonstrate that Egr-1 may bind ORF50P
with a greater affinity at positions between
2100 –
276 bp
(ORF50P8) compared to
22173 –
22149 bp (ORF50P3). However,
Figure 3. KSHV RTA and Egr-1 follow a similar expression
pattern during de novo KSHV infection. HEK293 cells were infected
with KSHV at 5 MOI, incubated at 37uC at different time points up to
48 hPI, and lysed. (A) Expression of KSHV RTA and Egr-1 were elevated
up to 6 hPI. SDS-PAGE was performed using uninfected (lane 1)o r
KSHV-infected cell lysates (lanes 2–7). The samples were run on a 10%
gel and transferred to a PVDF membrane. Western blotting was
performed using specific Egr-1 or KSHV RTA Abs. Abs targeting b-actin
were used as internal controls. (B) Analysis of ORF50 and egr-1
transcription. KSHV-infected HEK293 cells were lysed and RNA was
extracted. Next, cDNA was synthesized and subjected to quantitative
real-time PCR analysis. Baseline expression of genes at 1 hPI was
considered as 1-fold for comparisons. Each point denotes the
average6S.D. (error bars) of three experiments.
doi:10.1371/journal.pone.0033364.g003
Resveratrol Inhibits KSHV Reactivation
PLoS ONE | www.plosone.org 5 March 2012 | Volume 7 | Issue 3 | e33364Resveratrol Inhibits KSHV Reactivation
PLoS ONE | www.plosone.org 6 March 2012 | Volume 7 | Issue 3 | e33364we did not observe any such differences in the binding affinity of
Egr-1 to ORF50P3 and ORF50P8 by EMSA using IVT Egr-1
(Fig. 1B, C). All the more, our data supports the need for Egr-1 to
bind both ORF50P3 and ORF50P8 for an optimal transcriptional
activity in luciferase reporter assays (Fig. 2C). This difference
observed in Egr-1 binding to both these domains could be due to
one or both the reasons: (i) IVT synthesized Egr-1 was used in
EMSA experiments; and (ii) the design of ChIP assay conducted in
this study was not to decipher the relative binding affinity of Egr-1
to these domains; instead was performed to just confirm if Egr-1
bound these domains, in vivo.
Although we previously noticed that the egr-1 and KSHV-
encoded ORF50 followed a similar expression pattern, the
experiments were conducted in TPA-induced cells to evaluate
their expression during the reactivation process [6]. The present
study discovered that the transcriptional activity of egr-1 and
ORF50 and their subsequent translation is comparable and
followed a similar pattern during de novo KSHV infection (Fig. 3).
However, enhanced cellular Egr-1 and viral RTA expression
during early stages of primary infection (Fig. 3) is not sufficient to
trigger a lytic infection [6]. These results suggest the following: (i)
the role of Egr-1.RTA signaling in initiating a lytic cycle of
infection during the course of initial infection of cells is limited;
and (ii) there is a missing element in the Egr-1.RTA driven
cellular events critical for inducing a productive replication.
In this study, transfection of cells with egr-1/pCDNA3.1(+)
resulted in a significant increase in virus-encoded ORF50
transcription followed by the expression of early-lytic ORF59
protein and late-lytic gene (ORF8) encoding gB (Fig. 4B, C); all of
which are indicators of an active lytic replication of KSHV
[12,28,29]. MAPK signaling was observed to regulate Egr-1
expression in cells transfected with egr-1/pCDNA3.1(+) (Fig. 4D).
Interestingly, treatment of KSHV-infected cells with TPA induces
a lytic replication via MAPK signaling [12,13]. In addition, Egr-1
is a downstream target of Raf/MEK/ERK signaling (Fig. 4D)
[6,30]. It is unclear at this time if the effect of egr-1/pcDNA3.1
over-expression resembles the milieu supporting a lytic infection in
vivo. It is important to remember that KSHV reactivation can be
regulated by other cellular factors including STAT6, NFkB, and
XBP-1 [31,32,33]. Thus, activation of a lytic infection may require
unique cellular factors under specific conditions or a combination
of factors. Further investigation is required to unravel the
environment(s) supporting virus reactivation under physiologically
relevant conditions; especially in terms of the different transcrip-
tion factors.
In order to support these findings, more physiological relevant
studies were performed by analyzing the effect of resveratrol on
KSHV-infected cells. Resveratrol, or trans-3,5,49-trihydroxystil-
bene, is a phytoalexin that is produced in various plants such as
grapes, berries, and peanuts in response to attacks by pathogens
[14]. Several reports provide evidence for resveratrol to exhibit
antiviral effects [27,34,35]. On the other hand, resveratrol has also
been shown to induce virus replication [36,37]. We have
demonstrated that resveratrol, in its chemical form, inhibits
Figure 4. Elevated Egr-1 induces KSHV lytic gene expression. (A) Elevated Egr-1 was observed in cells transfected with egr-1/pCDNA3.1(+).
BCBL-1 cells were untransfected, mock transfected, transfected with pcDNA3.1 or egr-1/pcDNA3.1. The cells to be used as controls (lanes 1–3) were
incubated at 37uC for 48 h while the cells transfected with egr-1/pcDNA3.1 were incubated for 24, 48, and 72 h, respectively. At the end of incubation,
the cells were lysed and the lysates were used to perform Western blotting. (B) Effect of elevated Egr-1 on KSHV ORF50 and ORF8 expression. BCBL-1
cells were untransfected or transfected as described above. RNA was extracted, cDNA was synthesized, and the expression of cellular egr-1; and KSHV
encoded ORF50 and ORF8 were analyzed by qRT-PCR. Baseline expression of genes was considered as 1-fold for comparisons. Each point denotes the
average6S.D. (error bars) of three experiments. (C) Expression of lytic proteins in BCBL-1 cells transfected with Egr-1. KSHV-infected cells were
untransfected, transfected with pcDNA3.1, or egr-1/pcDNA3.1 for 48 h. The stained cells examined using a confocal microscope (magnification662).
The average number of fluorescent cells were counted over five random fields and used for comparisons. (D) Enhanced egr-1 activates MAPK
signaling in BCBL-1 cells. KSHV-infected cells were untransfected, mock-transfected, transfected with pcDNA3.1(+), or egr-1/pcDNA3.1(+) for 48 h.
Each group of cells was left untreated or they were treated with 10 mM of U0126 1 h prior to transfection and remained throughout the incubation
period. Cell lysates were resolved on a 10% SDS-PAGE, transferred to a PVDF membrane, and Western blotting was performed using specific
antibodies. (E) U0126 inhibits phosho-ERK1/2 and Egr-1. Briefly, BCBL-1 cells were treated with different concentrations of U0126. Following 24 h
incubation, the cells were lysed and the lysates were used to perform Western blotting as per earlier protocols using specific antibodies.
doi:10.1371/journal.pone.0033364.g004
Figure 5. Resveratrol inhibits Egr-1 and KSHV ORF50 expression during early stages of infection. (A) Resveratrol inhibited egr-1
expression by as early as 6 hPI in HEK293 cells. HEK293 cells were infected with 5 MOI of KSHV for 2 h at 37uC. After infection, the cells were washed
and cultured in growth medium in the presence or absence of different concentrations of resveratrol for 4 h. At the end of incubation, the cells were
lysed, RNA was extracted, cDNA was synthesized, and egr-1 levels were analyzed by qRT-PCR. Each point denotes the average6S.D. (error bars)o f
three experiments. (B) Resveratrol inhibits MAPK activity during de novo KSHV infection. HEK293 cells were mock-infected or infected with 5 MOI of
KSHV for 2 h at 37uC. After infection, the cells were washed and cultured in growth medium in the presence or absence of 100 mM of resveratrol for
48 h. The cells were lysed using gold lysis buffer (GLB) and the lysates were resolved on a 10% SDS-PAGE, transferred to a PVDF membrane, and
Western blotting was performed using specific antibodies.
doi:10.1371/journal.pone.0033364.g005
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RDS significantly inhibited KSHV reactivation in uninduced and
TPA-induced cells (Fig. 6A, B, C, D). While performing these
experiments we noticed that unfiltered RDS was able to inhibit
KSHV reactivation to a greater extent when compared to cells
treated with RDS that was passed through a 0.2 mm filter.
However, both treatments were able to significantly inhibit gene
products associated with KSHV reactivation (Fig. 6A, D). These
differences are likely due to the presence of unknown factors in
unfiltered RDS that may act in combination with resveratrol.
Incidentally, the decrease in the expression of RTA by RDS
coincided with a sharp decline in the ability of Egr-1 to bind
ORF50P as shown by the semi-quantitative ChIP assay (Fig. 6E).
Taken together, this is the first report to describe the role of
physiologically relevant RDS on KSHV infection.
Several cellular pathways are regulated by resveratrol including
apoptotic, NFkB, and all forms of MAPK signaling [14,38]. We
found resveratrol to inhibit expression of Egr-1 and phosphory-
lation of ERK1/2 resulting in suppression of KSHV reactivation
(Fig. 5 and 6). Very recent studies have established the fact that
resveratrol significantly lowers phosphorylation of ERK1/2
(directly upstream of Egr-1) in target cells, in vivo and in vitro
[25,26,39,40]. At this point in time, we are certain about the
ability of RDS to block TPA-induced virus reactivation. However,
further research is required to confirm if this ability of RDS to
promote viral latency is by its direct inhibitory effect on the
expression Egr-1 or the upstream MAPK signaling component(s),
namely ERK1/2 activity.
KSHV reactivation from latency is a complicated process which
is regulated by an intricate relationship between viral and cellular
factors. The method in which resveratrol may regulate KSHV
reactivation has yet to be fully understood. However, we propose
that resveratrol may inhibit KSHV reactivation by altering the
interactions between cellular Egr-1 and viral ORF50Pi na
Raf.MEK.ERK-dependent manner. All three MAPKs (ERK,
p38, and JNK) have been shown to positively regulate Egr-1
expression [41]. However, the role for active p38 MAPK is not
fully understood as it has been shown to reduce Egr-1 expression
in B-lymphocytes unlike ERK and JNK [42]. Further studies are
required to better understand the involvement of different MAPKs
on Egr-1 expression during KSHV infection. The findings
presented in this study open a Pandora’s Box of questions
pertaining to treating/managing a variety of viral infections using
RDS. Future studies are aimed at appreciating the cellular milieu
critical for the effectiveness of the MAPK associated signaling in
inducing virus reactivation. These findings may provide for more
useful applications to combat a variety of viral lytic infections.
Materials and Methods
Cells
HEK293 cells and BCBL-1 cells were cultured in DMEM and
RPMI (Invitrogen, Carlsbad, CA), respectively, as per earlier
studies [6,43].
Antibodies
Rabbit antibodies to gB [44], RTA [6]; and mouse antibodies to
ORF59 (Bryan et al., 2006) were used in this study. Rabbit
antibodies to phospho-ERK1/2, total ERK1/2, actin, and Egr-1
(15F7; monoclonal antibodies) purchased from Cell Signaling
Technology, Beverly, MA were used in this study. Mouse (S-25)
and rabbit (15F7) antibodies to Egr-1 purchased from Santa Cruz
biotechnologies, Inc. (Santa Cruz, CA) were used in Immunoflu-
orescence assay (IFA) and Western blotting experiments, respec-
tively. Additionally, rabbit polyclonal antibodies (588) to Egr-1 was
used in gel shift and chromatin immunoprecipitation assays (Santa
Cruz Biotechnology, Santa Cruz, CA).
Vectors
We used egr-1/pCDNA3.1(+) and gL/pCDNA3.1(+) vectors in
this study. Both these vectors have been described elsewhere [6].
Reagents
U0126 (Promega, Madison, WI) and Resveratrol (Enzo Life
Sciences, Plymouth Meeting, PA), resuspended in DMSO, and
stored at 220uC. Finally, 4Resveratrol
TM liquid supplement
(Genesis Today, Austin, TX) was filtered with a 0.2 mm filter or
left unfiltered and used in this study. 4Resveratrol
TM dietary
supplement (RDS) contains 575 mg of resveratrol per 1 oz of
serving. In all of this study, we used RDS at a final concentration
of 100 mM.
In vitro transcription and translation (IVT)
IVT of egr-1/pCDNA3.1(+) and gL/pCDNA3.1(+) was con-
ducted as per earlier studies [45] using the TNT-coupled rabbit
reticulocyte lysate system (Promega).
Primary infection of HEK293 cells
HEK293 cells were infected as per earlier procedures (25).
Figure 6. RDS reduces the Egr-1/ORF50 association in vivo. (A) RDS lowers Egr-1 and KSHV RTA expression. KSHV-infected BCBL-1 cells were
synchronized in S phase and untreated or treated using 20 ng/ml of TPA for 2 h. Each group of cells was left untreated or was further treated using
filtered or unfiltered RDS containing 100 mM of resveratrol. The cells were incubated at 37uC for 6 h and lysed. The lysates were resolved on a 10%
SDS-PAGE, transferred to a PVDF membrane, and Western blotting was performed using specific antibodies. (B) RDS reduces the number of KSHV-
infected cells undergoing reactivation in HEK293 cells. Mock-infected, KSHV-infected, and KSHV-infected cells in the presence of RDS containing
100 mM resveratrol were stained using monoclonal mouse anti-Egr-1 IgGs and rabbit peptide antibodies targeting KSHV RTA and examined under a
fluorescent microscope (magnification6100). (C) Overexpression of Egr-1 is unable to overcome RDS-mediated inhibition of virus reactivation. BCBL-
1 cells were transiently transfected using pcDNA3.1(+)o regr-1/pcDNA3.1(+) and subsequently treated with unfiltered RDS containing 100 mMo f
Resveratrol for 6 h. RNA was extracted, cDNA was synthesized, and egr-1 and KSHV ORF50 were analyzed by qRT-PCR. Each point denotes the
average6S.D. (error bars) of three experiments. (D) RDS lowers egr-1 and KSHV ORF50 transcriptional activity. BCBL-1 cells were synchronized in S
phase, treated with 20 ng/ml of TPA, and treated using filtered or unfiltered RDS containing 100 mM of resveratrol as before. RNA was extracted,
cDNA was synthesized, and egr-1 and KSHV ORF50 were analyzed by qRT-PCR. Each point denotes the average6S.D. (error bars) of three experiments.
Columns with different alphabets are statistically significant (P,0.05) by LSD. (E) RDS inhibits the ability of Egr-1 to bind KSHV ORF50 in vivo. BCBL-1
cells were synchronized and treated with TPA as before. The cells were further treated using unfiltered RDS containing 100 mM of resveratrol and
incubated for 6 h. ChIP assays were performed using 2 mg of specific Egr-1 Abs. Semi-quantitative PCR experiments were performed using samples
from 1% input DNA and IP samples in order to determine the expression of ORF50P8. Respective cDNA at 10, 15, 20, 25, and 30 cycles were resolved
on a 2% agarose gel. Specific antibodies to histone H3 and nonspecific IgGs were used to IP sample chromatin and served as positive and negative
controls, respectively.
doi:10.1371/journal.pone.0033364.g006
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In this study, we synchronized BCBL-1 cells in S phase of cell
cycle as per earlier protocols [46].
Western blotting
Equal amounts (20 mg) of protein was used in Western blotting
experiments as per earlier studies [47].
qRT-PCR
The qRT-PCR was performed using the synthesized cDNA in a
25 ml reaction volume to analyze the expression of ORF50, egr-1,
and M6PR as per earlier protocols [47].
Transfection of target cells
Target cells were transfected with pCDNA3.1(+), egr-1/
pCDNA3.1(+), gL/pCDNA3.1(+) using GeneJammer transfection
reagent (Stratagene, La Jolla, CA) as per earlier studies [12].
IFA
Target cells were fixed for 10 min in ice cold acetone and
washed thrice in phosphate buffered saline (PBS). These cells were
sequentially stained with mouse anti-ORF59 antibodies and goat
anti-mouse FITC as per earlier studies [12]. The stained cells were
further incubated for 20 min on ice with 5 mM SYTO Red (a
nuclear stain; Invitrogen) before being analyzed with a laser-
scanning LSM 510 Carl Zeiss confocal microscope. In another set
of experiments, acetone fixed cells were incubated with a
combination of mouse anti-Egr-1 IgGs and rabbit anti-RTA for
45 min at room temperature (RT), and incubated with a
combination of goat anti-mouse FITC and goat anti-rabbit
TRITC) for 30 min at RT. Stained cells were washed in PBS,
mounted by using an anti-fade reagent containing DAPI (4,6-
diamidino-2-phenylindole; Molecular Probes) and examined
under a Nikon fluorescent microscope with appropriate filters.
EMSA
IVT products of Egr-1 or KSHV gL were evaluated by EMSA
for DNA binding using several 25 bp digoxygenin (DIG)-labeled
probes containing sequences from the ORF50P (Table 1) as per
earlier studies [6]. For a supershift, the cellular lysate was
incubated with rabbit monoclonal antibodies to Egr-1 or
nonspecific IgG at 37uC for 30 min prior to the addition of the
DIG-labeled probe. All samples were run on a 4% non-
denaturing gel for approximately 1.5 h and transferred to a
PVDF membrane. The protein:DNA interaction was detected
using the CSPD detection system (Roche Applied Science).
Luciferase Assay
Target cells were transiently co-transfected using appropriate
pGL3 and internal control pRL-TK contructs (Promega) and
pcDNA3.1(+) vectors (Invitrogen). The total amount of DNA used
per sample was approximately 2 mg. Following 48 h post-transfec-
tion, cells were harvested and Firefly and Renilla luciferase activities
were analyzed using the dual luciferase system (Promega). Luciferase
activity was monitored using a Turner Systems Luminometer
(Sunnyvale, CA) as per earlier protocols [6]. The relative luciferase
activity was calculated by normalizing ORF50P luciferase activity to
control Renilla luciferase activity. The results were plotted as a
percentage of the activity of the empty pGL3 vector.
Chromatin Immunoprecipitation Assay
BCBL-1 cells were treated with a final concentration of 1%
formaldehyde and crosslinked for 10 min at RT. Crosslinking
was stopped by addition of glycine at a final concentration of
0.125 M for 5 min. The cross-linked cells were washed in 16
PBS and counted so that approximately 10
7 cells were used in
each immunoprecipitation (IP) reactions. Nuclei from the cells
were purified and lysed to collect chromatin. Chromatin was
sheared to approximately 500 bp using a Bioruptor sonicator
(Diagenode, Sparta, NJ). Lysates containing the chromatin were
pre-cleared using 35 ml of Protein A sepharose beads (Amersham
Biosciences) in pre-IP dilution buffer for 30 min at 4uC. The
samples were centrifuged to remove beads and the lysate was
recovered. After setting aside input controls, primary antibodies
were added to the samples and incubated overnight at 4uC. The
DNA/protein complexes were IP using protein A beads for 4 h
at 4uC and then washed using various ChIP wash buffers.
Following elution, proteinase K was added to the complexes and
incubated at 65uC overnight in order to reverse the crosslinks.
The DNA samples were purified using phenol/chloroform
extraction, resuspended in 16 TE buffer, and finally analyzed
by polymerase chain reaction (PCR). PCR was performed using
platinum pfx polymerase (Invitrogen, Carlsbad, CA) as per
standard protocols. PCR amplification of the precipitated DNA
was performed using primers that targeted ORF50P3, ORF50P8,
and ORF50PNP regions (Table 1): ORF50P3 forward, 59-
TTCCCTTTTGACCTGCGTGCG-39 and reverse, 59-
CGAAGTTTGACGGCCTATACTGTAGG-39 (178 bp prod-
uct); ORF50P8 forward, 59-CTACCGGCGACTCATTAAGC-
39, and reverse, 59-GTGGCTGCCTGGACAGTATT-39
(126 bp product); ORF50PNP forward, 59-CTAGGGGCG-
GAAATTTACAA-39, and reverse, 59-GGTTCCAGGGCTG-
TAATCACT-39 (131 bp product).
Supporting Information
Figure S1 Resveratrol inhibits Egr-1 expression in the
absence of KSHV infection. HEK293 cells were mock-
infected by incubating with growth medium for 2 h at 37uC.
These cells were washed and cultured in growth medium in the
presence or absence of 100 mM of resveratrol for 48 h. The cells
were lysed using gold lysis buffer (GLB) and the lysates were
resolved on a 10% SDS-PAGE, transferred to a PVDF
membrane, and Western blotting was performed using specific
antibodies.
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